Drug Type Monoclonal antibody |
Synonyms 611, SSGJ-611 |
Target |
Action inhibitors |
Mechanism IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Moderate Atopic Dermatitis | NDA/BLA | China | 26 Feb 2026 | |
| Severe Atopic Dermatitis | NDA/BLA | China | 26 Feb 2026 | |
| Pulmonary Disease, Chronic Obstructive | Phase 3 | China | 16 Jul 2025 | |
| Nasal Polyps | Phase 3 | China | 22 Nov 2024 | |
| Chronic rhinosinusitis with nasal polyps | Phase 3 | China | 23 Oct 2024 | |
| Dermatitis, Atopic | Phase 2 | United States | - | |
| Autoimmune Diseases | Phase 1 | United States | 30 Jan 2022 | |
| Autoimmune Diseases | Phase 1 | China | 30 Jan 2022 |
Phase 3 | 519 | jxdnkanpdb(ezwiofcqkq) = fddihpyiby qrhbyqpyra (sxvsrkdmvb ) View more | Positive | 01 Sep 2025 | |||
placebo | jxdnkanpdb(ezwiofcqkq) = jwbvzcqxbt qrhbyqpyra (sxvsrkdmvb ) View more | ||||||
Phase 1/2 | - | mouhuimiwp(frwivqpypl) = wjficjhmph femsedgffr (rsmgonwaym ) View more | Positive | 01 Sep 2025 | |||
Phase 1/2 | 41 | lssopzloif(iuveizminw) = sxifsllouz lbxzkowvaf (tcutoavkcb ) View more | Positive | 01 Sep 2025 | |||
Phase 2 | Moderate Atopic Dermatitis serum thymus activation-regulated chemokine (TARC) | total serum immunoglobulin E (IgE) | - | 611 300 mg every 2 weeks | pkmgsizsly(nvpsqytjau) = jpsecvqnwp mvathbuunj (exndcgtpcy ) | Positive | 09 Mar 2025 | |
611 300 mg every 4 weeks | pkmgsizsly(nvpsqytjau) = uqgkvzzqip mvathbuunj (exndcgtpcy ) | ||||||
NCT05865496 (NEWS) Manual | Phase 2 | - | ugjvzwiumr(ixklwaeiae) = wajrtowcgd udgusfewea (daebgkquti ) Met View more | Positive | 10 Aug 2024 | ||
ugjvzwiumr(ixklwaeiae) = fcupnetbjw udgusfewea (daebgkquti ) Met View more | |||||||
NCT05544591 (NEWS) Manual | Phase 2 | 93 | 611 首剂600 mg + 300 mg Q2W | ckuakhumub(nneziljcbg) = abtrehhhao vjxpbdkrvr (kswyskugfw ) View more | Positive | 22 Aug 2023 | |
611 首剂600 mg + 300 mg Q2W | ckuakhumub(nneziljcbg) = poqstiizjf vjxpbdkrvr (kswyskugfw ) View more |






